Silo Pharma, Inc.
SILO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SILO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SILO
Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on developing novel therapeutics for underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and CNS diseases, with lead program SPC-15 targeting PTSD and stress-induced anxiety disorders [sec · filed 2025-10-29].
Key risk: No profitable operations history
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for Silo Pharma, Inc..
Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on developing novel therapeutics for underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and CNS diseases, with lead program SPC-15 targeting PTSD and stress-induced anxiety disorders [sec · filed 2025-10-29].
- Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company [sec · filed 2025-10-29].
- Lead program SPC-15 is an intranasal drug targeting PTSD and stress-induced anxiety disorders [sec · filed 2025-10-29].
- As of June 30, 2026, the company had cash and cash equivalents of $3.3M, short-term investments of $1.95M, and working capital of $4.65M [sec_mda · as of 2026-08-13].
- The company reported a net loss of $2.48M and used $1.60M in operations during the six months ended June 30, 2026, with an accumulated deficit of $21.97M [sec_mda · as of 2026-08-13].
- Management believes current cash and short-term investments will fund obligations for at least twelve months from the date of the filing [sec_mda · as of 2026-08-13].
What works
- The company has a lead program (SPC-15) targeting large, underserved markets such as PTSD and stress-induced anxiety disorders [sec · filed 2025-10-29].
- Management states that current cash and short-term investments are sufficient to meet obligations for at least twelve months from the filing date [sec_mda · as of 2026-08-13].
- The company is exploring novel therapies including both conventional drugs and psychedelic formulations, potentially addressing multiple CNS conditions [sec · filed 2025-10-29].
What to weigh
- The company is a developmental-stage entity with no history of profitable operations and requires additional financing to fund future operations [sec · filed 2025-04-25].
- As of June 30, 2026, the company had an accumulated deficit of $21.97M and reported a net loss of $2.48M for the first half of 2026 [sec_mda · as of 2026-08-13].
- The company faces risks related to the initiation, timing, cost, and success of preclinical and clinical studies, with no guarantee of advancing product candidates [sec · filed 2025-01-02].
From the filings
Quoted directly from source documents.
The company is a developmental-stage biopharmaceutical and cryptocurrency treasury company focused on underserved CNS conditions.
“We are a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Our therapeutic focus is on developing novel therapeutics that address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases.”
SEC filings · October 29, 2025
Lead program SPC-15 is an intranasal drug targeting PTSD and stress-induced anxiety disorders.
“The Company's lead program, SPC-15, is an intranasal drug targeting PTSD and stress-in”
SEC MD&A · October 29, 2025
As of June 30, 2026, the company had cash and cash equivalents of $3.28M, short-term investments of $1.95M, and working capital of $4.65M.
“As of June 30, 2026, we had working capital of $4,647,793, $1,950,147 in short-term investments, and $3,277,095 in cash and cash equivalents.”
SEC MD&A · August 13, 2026
The company had an accumulated deficit of $21.97M as of June 30, 2026.
“Additionally, we have an accumulated deficit of $21,972,335 on June 30, 2026.”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- No profitable operations history — The company has only a limited history and no profitable operations, requiring additional financing to fund operations [sec · filed 2025-04-25].
- Clinical development uncertainty — The initiation, timing, cost, and success of preclinical and clinical studies are uncertain, and product candidates may not advance [sec · filed 2025-01-02].
- Accumulated deficit and net losses — As of June 30, 2026, accumulated deficit was $21.97M and net loss for the first half of 2026 was $2.48M [sec_mda · as of 2026-08-13].
- Dependence on future financing — The company will require additional financing to fund operations, and there is no guarantee of obtaining sufficient capital [sec · filed 2025-04-25].
What to watch
- Progress of lead program SPC-15 in preclinical and clinical studies for PTSD and stress-induced anxiety disorders [sec · filed 2025-10-29].
- Ability to secure additional financing to support ongoing research and development [sec · filed 2025-04-25].
- Cash runway and burn rate, with management stating current funds cover at least twelve months from the filing date [sec_mda · as of 2026-08-13].
- Advancement of other pipeline candidates, including SP-26 for chronic pain management [sec · filed 2025-01-02].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Silo Pharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Silo Pharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
20.2 months
D/E 0.22 · 0% dilution
Lead: Preclinical
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$379K
| Holder | Shares | Value |
|---|---|---|
| advisorshares investments llc | 663,965 | $239K |
| geode capital management, llc | 180,031 | $65K |
| susquehanna international group, llp | 62,795 | $23K |
| jane street group, llc | 44,763 | $16K |
| vanguard capital management llc | 22,442 | $8K |
| citadel advisors llc | 21,448 | $8K |
| xtx topco ltd | 17,083 | $6K |
| two sigma securities, llc | 14,503 | $5K |
| vanguard fiduciary trust co | 13,100 | $5K |
| state street corp | 12,500 | $4K |
Showing top 10 of 14 institutional holders of Silo Pharma, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 29, 2026- % of float
- 3.3%
- Days to cover
- 0.1
- Shares short
- 522,541
- Daily short volume (May 19, 2026)
- 32.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SILO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Silo Pharma, Inc.?
Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on developing novel therapeutics for underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and CNS diseases, with lead program SPC-15 targeting PTSD and stress-induced anxiety disorders [sec · filed 2025-10-29].
What is Silo Pharma, Inc.'s lead drug candidate?
Silo Pharma, Inc.'s most advanced tracked candidate is SP-26 (Preclinical) for Fibromyalgia and chronic pain.
Who is the CEO of Silo Pharma, Inc.?
Mr. Eric Weisblum is the chief executive officer of Silo Pharma, Inc. (SILO).
Where is Silo Pharma, Inc. headquartered?
Silo Pharma, Inc. (SILO) is headquartered in Sarasota, FL, United States.
What therapeutic areas does Silo Pharma, Inc. focus on?
Silo Pharma, Inc. develops therapies across Neurology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.